NeuroFrontiers: Recent Episodes
ReachMD
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health. So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zarazuela Zolkipli-Cunningham, MBChB, MRCP
Guest: Oscar H. (Hank) Mayer, MD
Thymidine kinase 2 deficiency (TK2d) is a rare mitochondrial myopathy that can involve multiple organ systems, requiring care from different specialties. Given that need for multidisciplinary coordination, Dr. Charles Turck speaks with Drs. Hank Mayer and Zuela Zolkipli-Cunningham to learn how we can improve communication and collaboration across the care team throughout the diagnostic and management journey. Coming to us from the Children's Hospital of Philadelphia, Dr. Mayer is the Director of the Pulmonary Function Laboratory, and Dr. Zolkipli-Cunningham is the Director of Clinical Research in the Mitochondrial Medicine Frontier Program.
No Label: Michael Levy, MD, PhD
No Label: Peter V. Sguigna, MD
What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.
Guest: Jaime Imitola, MD
As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments, investigational approaches, and unproven interventions marketed through stem cell tourism. Hear more as Dr. Jaime Imitola discusses the current landscape of stem cell therapies in MS, the risks associated with unregulated treatments, and the importance of patient education and evidence-based guidance. Dr. Imitola is the Vice Chair for Research of the Department of Neurology and the Director of the Division of Multiple Sclerosis and Translational Neuroimmunology at UConn Health. He also spoke about this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.
Guest: Elizabeth S. Gromisch, PhD
Cognitive changes are a common but complex aspect of multiple sclerosis care, making practical and accessible screening strategies essential. In this program, Dr. Elizabeth Gromisch explores both traditional and digital cognitive screening tools for MS and shares real-world insights on selecting and implementing assessments across a range of clinical settings. Dr. Gromisch is a research neuropsychologist at the Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience Research at Mount Sinai Rehabilitation Hospital, Trinity Health of New England. She also discussed this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Bethany Lussier, MD
Patients often present with respiratory symptoms that don’t quite align with typical pulmonary findings. So what clues should raise our suspicion that something beyond primary lung disease might be driving their condition? Joining Dr. Charles Turck to talk about the pulmonologist’s role in identifying respiratory manifestations of thymidine kinase 2 deficiency (TK2d) is Dr. Bethany Lussier. She shares the hallmark features to look out for, like orthopnea and hypoventilation, as well as best practices for using pulmonary function testing and inspiratory pressure measures to distinguish muscle weakness from primary lung disease. Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center in Dallas, where she's also a member of the Division of Pulmonary and Critical Care Medicine.
Host: Alexandria May, PharmD, BCPS
Guest: Kaitlin Batley, MD
Fatigue and muscle weakness may seem routine, but when do they signal an underlying condition like thymidine kinase 2 deficiency (TK2d)? To find out, Dr. Alexandria May speaks with Dr. Kaitlin Batley, Director of the Pediatric Neuromuscular Program at Children’s Health and an Assistant Professor of Pediatrics and Neurology at UT Southwestern Medical Center. They discuss how multisystem involvement can help distinguish TK2d from more common neuromuscular disorders and how we can achieve diagnostic clarity through advanced genetic testing, metabolic evaluation, and muscle biopsy.
Guest: Henry Kaminski, MD
Myasthenia gravis is an unpredictable condition, with symptoms and treatment responses that can vary widely from one patient to the next. Tune in to hear Dr. Henry Kaminski explain how to navigate this variability and make thoughtful, individualized treatment decisions. Dr. Kaminski is the Meta A. Neumann Professor of the Department of Neurology at The George Washington University School of Medicine and Health Sciences in Washington.
Host: Brian P. McDonough, MD, FAAFP
Guest: Austin Larson, MD
Emerging research on thymidine kinase 2 deficiency (TK2d) provides new insights into its global genetic prevalence and variability across genetic ancestries. By combining clinical literature with large genomic databases, investigators estimated disease incidence using carrier frequency under Hardy-Weinberg assumptions, uncovering significant differences between populations and key pathogenic variants. Joining Dr. Brian McDonough to discuss the findings and their implications for improving diagnostic accuracy and refining genetic testing strategies is Dr. Austin Larson. He's an Associate Professor of Pediatric Clinical Genetics and Metabolism at the University of Colorado Anschutz, and he presented these findings at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference.
Guest: Aaron Miller, MD
Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emerging evidence, explains how these updates are reshaping diagnostic pathways, and addresses practical challenges in implementation. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York. He also spoke about this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.
Guest: Adil Harroud, MD
Guest: Dylan Hamitouche
Host: Ryan Quigley
Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS, a topic they presented on at the 2026 ACTRIMS Forum. Dr. Harroud is a neurologist and the co-leader of the Neuroimmunology Diseases Research Group at the Montreal Neurological Institute at McGill University. Mr. Hamitouche is a medical student at McGill University.
Guest: Raphael Schneider, MD, PhD, FRCPC, CIP
Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael’s Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.
Guest: Jennifer Yang, MD
Emerging evidence shows that children with multiple sclerosis exhibit accelerated biological aging. Learn more about the potential implications with Dr. Jennifer Yang, who spoke about this topic at the 2026 ACTRIMS Forum. She's an Assistant Professor of Neurosciences at the UC San Diego School of Medicine and the Division of Pediatric Neurology at Rady Children's Hospital.
Host: Jerome Lisk, MD, MBA, M.S., FAAN
Guest: Michael Salvatore, PhD
Guest: Vicki Nejtek-Salvatore, PhD
Translational research is reshaping the way we understand, detect, and manage Parkinson’s disease. To learn more about how current research efforts are uncovering early biomarkers and redefining intervention strategies, Dr. Jerome Lisk sits down with Dr. Michael Salvatore and Dr. Vicki Nejtek-Salvatore, professors at University of North Texas Health Science Center in Fort Worth and co-founders of the Parkinson Discovery Institute in Fort Worth, Texas.
Guest: Ashvini Keshavan, MRCP, PhD
Very few patients in UK memory services receive an Alzheimer’s diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded by the Blood Biomarker Challenge, a multi-million-pound program supported by the Alzheimer's Society, Alzheimer's Research UK, and players of People's Postcode Lottery—aims to close this gap by evaluating the real-world integration of blood-based biomarkers into standard NHS memory care pathways. Join Dr. Ashvini Keshavan as she discusses how this approach may impact diagnostic accuracy, treatment access, and healthcare resource use across the UK. Dr. Keshavan is a Senior Clinical Research Fellow and Honorary Consultant Neurologist specializing in Alzheimer’s disease biomarkers at the University College London, and this topic was presented as a poster at the 2025 CTAD conference.
Guest: Le Hua, MD
Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Sergio Baranzini, PhD
In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Guest: Michael Levy, MD, PhD
Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Host: Jennifer Caudle, DO
Guest: Katie Beadon, MD, MASc, FRCPC
Multifocal motor neuropathy (MMN) is a chronic, immune-mediated motor neuropathy that can mimic other neuromuscular disorders1-3 and is one of the few motor neuron disorders that is treatable.4 However, disease severity correlates with the length of time a patient remains untreated, which is why early recognition and treatment initiation is essential for preserving long-term motor function.5-6 Joining Dr. Jennifer Caudle to discuss the diagnosis and management of MMN is Dr. Katie Beadon, Co-Director of St. Paul’s Hospital Immunotherapy in Neurology Clinic and an Assistant Clinical Professor at the University of British Columbia in Vancouver.
References:
- Guimarães-Costa R, Bombelli F, Léger JM. Multifocal motor neuropathy. Presse Med. 2013;42(6 Pt 2):e217-24. doi:10.1016/j.lpm.2013.01.057
- Beadon K, Guimarães-Costa R, Léger JM. Multifocal motor neuropathy. Curr Opin Neurol. 2018;31(5):559-564. doi:10.1097/WCO.0000000000000605
- Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48-58. doi:10.1038/nrneurol.2011.175
- Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140-148. doi:10.1136/jnnp-2019-321532
- Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75(9):818-25. doi:10.1212/WNL.0b013e3181f0738e
- Van …
Host: Ryan Quigley
A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Guest: Marisa McGinley, DO
The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.
Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.
Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care.
Guest: David Gate, PhD
Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, dives into his research on this subject and explains how chromatin accessibility in proinflammatory genes and T-cell receptor changes link to neurological pathology.
Guest: Marisa McGinley, DO
Multiple sclerosis (MS) treatment has transformed dramatically, with a wide range of high-efficacy options currently available. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explores how advancements in drug availability, administration methods, and efficacy are reshaping care, with a focus on sequencing strategies and the growing movement toward early, aggressive treatment. Learn how to integrate patient preferences, comorbidities, and shared decision-making into personalized therapy plans.
Guest: Marisa McGinley, DO
Multiple sclerosis (MS) presents with far more than just mobility issues—fatigue, spasticity, bladder and bowel dysfunction, cognitive changes, and mood disorders are frequently underrecognized but deeply impactful. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explains how to identify subtle clinical changes, utilize patient-reported outcomes, and engage in proactive symptom discussions that support timely interventions.
Guest: Marisa McGinley, DO
Multiple sclerosis (MS) presents a diverse range of symptoms that require coordinated, expert care. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, provides practical strategies for neurologists to serve as the central point of contact for patients with MS, initiate targeted treatments, and engage a variety of specialty teams in collaborative management.
Guest: John Golden
Host: Michael Greenberg, MD
Neuro-responsive EEG headphones are helping healthcare professionals combat burnout by promoting calm, focus, and resilience. Backed by neuroscience and real-time brain monitoring, this personalized technology blends music and neurofeedback to optimize mental states and reduce stress. Hear from Vital Neuro CEO John Golden as he joins Dr. Michael Greenberg to discuss this device's impact in clinical workflows, from pre-op anxiety management to enhanced physician well-being.
Guest: John Golden
Guest: Michael Greenberg, MD
EEG-guided headphones from Vital Neuro present a new frontier in anxiety management through personalized, real-time neurofeedback and music therapy. Dr. Michael Greenberg speaks with Vital Neuro CEO John Golden about the science behind these devices, their effectiveness in reducing anxiety symptoms, and how they can integrate into daily life.
Guest: Riley Bove, MD, MMSc
Many patients with multiple sclerosis (MS) experience neurogenic bladder symptoms—ranging from urgency and incontinence to retention and infection risk—but these issues are often underprioritized in care. Based on recent research, remote, commercially available bladder monitoring tools can help address this unmet need and uncover day-to-day fluctuations in bladder function. To learn more about this research, tune in to hear from Dr. Riley Bove. Not only is Dr. Bove a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences, but she also presented a session on this exact topic at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting.
Guest: John A. Morren, MD, FAAN, FAANEM
The symptom variability, prolonged asymptomatic periods, and inconsistent presentations of generalized myasthenia gravis (gMG) often lead to significant diagnostic delays and misdiagnoses. Based on recent studies, these delays then correlate with increased disease severity, longer time to symptom control, and worsened quality of life. Here to help uncover the hidden toll of diagnostic delays on patients with gMG is Dr. John Morren. He’s the Program Director of the Neuromuscular Medicine Fellowship at Cleveland Clinic and an Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Guest: Riley Bove, MD, MMSc
From pregnancy planning and postpartum relapse risk to the overlapping symptoms of menopause, women with multiple sclerosis (MS) face unique challenges throughout the reproductive lifespan. Here to share key takeaways from her session at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting that focused on how we can better care for these patients is Dr. Riley Bove, a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences.
Host: Jerome Lisk, MD, MBA, M.S., FAAN
Guest: Emile Maamary
Guest: Mark Elias
For patients with who struggle with daily activities due to Parkinson's disease or essential tremor, treatment options are mostly limited to medication and invasive surgery. That's why Steadiwear co-founders Mark Elias and Emile Maamary developed an FDA-registered glove engineered to suppress hand tremors. Dr. Jerome Lisk sits down with Mr. Elias and Mr. Maamary to learn more about the device and its potential real-world impacts.
Guest: Rosaline Quinlivan
From sustained therapy and emergency planning to psychological support, coordinated care is essential as patients with Duchenne muscular dystrophy (DMD) transition into adulthood. Explore multidisciplinary approaches to optimize function, independence, and quality of life in adults with DMD with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.
Guest: Rosaline Quinlivan
As patients with Duchenne muscular dystrophy (DMD) transition from pediatric to adult care, they may encounter healthcare professionals—from primary care to emergency medicine—without prior experience managing their condition. Explore critical gaps in adult services for DMD and gain practical insights to help deliver timely, informed, and compassionate care with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.
Guest: Andrew J. Solomon, MD
Accurately diagnosing multiple sclerosis (MS) involves understanding the diagnostic criteria, recognizing red flags to avoid misdiagnosis, and keeping up with new tools. Dr. Andrew Solomon, Professor and Interim Chair of the Department of Neurological Sciences and Chief of the Multiple Sclerosis Division at the University of Vermont, walks through the most difficult aspects of diagnosing patients with MS and potential breakthroughs reshaping how we approach these challenges. Dr. Solomon also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jason Ackrivo, MD, MSCE
Guest: Bethany Lussier, MD
Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient’s respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.
Guest: Prajwal Ciryam, MD, PhD
Traumatic brain injuries (TBIs) trigger a rapid transcriptional response in the choroid plexus, dominated by chemokines that attract neutrophils. Join Dr. Prajwal Ciryam, Assistant Professor of Neurology at the University of Maryland School of Medicine, as he explains how this early signaling may represent a critical window for modulating inflammation in the injured brain. Dr. Ciryam also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.
Guest: Kelly Sloane, MD
For patients who experience aphasia after a stroke, intervention and social support are crucial for recovery. Dr. Kelly Sloane, Assistant Professor of Neurology at the University of Pennsylvania, highlights how timely therapy and strong support systems can help rebuild both language and confidence in these patients. Dr. Sloane also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.
Guest: Lauren Schaff, MD
Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.
Guest: Beth Ann Malow, MD, MS
The impacts of climate change present a growing threat to brain health. Rising heat, air pollution, and oxidative stress appear to worsen conditions like stroke, dementia, and multiple sclerosis. Join Dr. Beth Malow as she outlines the essential role clinicians play in prevention and education. Dr. Malow is a Professor of Neurology and Pediatrics and the Vice Chair for Academic Affairs in the Department of Neurology at Vanderbilt University Medical Center.
Guest: Jennie Taylor, MD
The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.
Guest: Jennie Taylor, MD
Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.
Host: James R. Bateman, MD, MPH
Guest: Charles P. Vega, MD
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Charles P. Vega, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Host: James R. Bateman, MD, MPH
Guest: B. Joy Snider, MD, PhD
Guest: Jerome A. Barakos, MD
Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.
Guest: Christian Cordano, MD, PhD
While multiple kinds of animal models are commonly used to study multiple sclerosis (MS), they are not always ideal for getting the full picture of the disease. To address these gaps, a new CAR T-cell-based model provides a reproducible disease course, discrete lesion formation, and an improved platform for testing remyelination therapies. Dr. Christian Cordano, Associate Researcher of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains how this approach aims to overcome key limitations of traditional research models for MS. Dr. Cordano also spoke on this topic at the ACTRIMS Forum 2025.
Guest: Amber Salter, PhD
A recent study examined the association between comorbidities, adverse events, and early trial discontinuation in phase III clinical trials for disease-modifying therapies for multiple sclerosis. Join Dr. Amber Salter as she explains her findings and implications for clinical practice, including personalized treatment approaches. Dr. Salter is an Associate Professor of Biostatistics at UT Southwestern Medical Center, and she presented on this research at the ACTRIMS Forum 2025.
Guest: Michael Kornberg, MD, PhD
A recent study found that a ketogenic diet may have anti-inflammatory effects in patients with multiple sclerosis (MS), potentially reducing relapse risk. However, this diet also comes with a variety of risks and challenges. Hear from Dr. Michael Kornberg as he explains the potential benefits and drawbacks of this approach. Dr. Kornberg is an Assistant Professor of Neurology at Johns Hopkins University School of Medicine, and he presented on this topic at the ACTRIMS Forum 2025.
Guest: Dalia Rotstein, MD, MPH
Prodromal symptoms are common in neurologic and inflammatory conditions like multiple sclerosis (MS). Recent evidence suggests that prodromal symptoms also exist in patients with neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody disease (MOGAD). Join Dr. Dalia Rotstein as she explains how emerging research is providing insight into these symptoms, potentially informing our diagnostic strategies.
Guest: Cristin Welle, PhD
To address the concerning effects of demyelinating events in patients with multiple sclerosis (MS), a recent study explored whether neuromodulation could support myelin repair and restoration of function. Learn more as Dr. Cristin Welle explains how vagus nerve stimulation has the potential to play a role in remyelination. Dr. Cristin Welle is a Professor of Neurosurgery and Physiology at the University of Colorado Anschutz Medical Campus, and she spoke about this topic at the ACTRIMS Forum 2025.
Guest: Amy Kuceyeski, PhD
In patients with multiple sclerosis, lesions in white matter can disrupt brain connectivity, leading to cognitive and motor impairments. Join Dr. Amy Kuceyeski as she discusses the pathophysiology behind structural disconnectivity and shares insights on new tools being developed to more accurately identify it in patients with multiple sclerosis. Dr. Kuceyeski is a Professor of Mathematics in Radiology and Neuroscience at Weill Cornell Medicine, and she spoke on this topic at the ACTRIMS Forum 2025.
Guest: Natalie Bareis, PhD, LMSW
Despite the availability of effective treatments for schizophrenia spectrum disorders, many patients are not receiving minimally adequate care based on a recent study. Tune in to hear Dr. Natalie Bareis discuss barriers to care, including the impact of substance use disorders and the limited availability of specialized programs, as well as how we can improve access and outcomes for patients with schizophrenia spectrum disorders. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.
Guest: Natalie Bareis, PhD, LMSW
A recent study on schizophrenia uncovered a significantly higher prevalence than previously estimated. The study also highlights ongoing struggles for patients, including low employment rates, poor general functioning, and limited access to adequate treatment. Join lead author Dr. Natalie Bareis as she discusses these findings and highlights the need for better policies and treatment accessibility. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.
Guest: Jonathan Strober, MD
Misinterpreted symptoms and limited access to treatment can make it difficult to manage myasthenia gravis among adolescents and young adults. Join Dr. Jonathan Strober as he explains how we can address gaps in care for this population. Dr. Strober is a Professor of Neurology at the University of California, San Francisco and the Director of the Neuromuscular Clinic at UCSF Benihoff Children’s Hospital.
Guest: Gil I. Wolfe MD, FAAN
Rozanolixizumab is a fast-acting myasthenia gravis treatment that reduces IgG levels by blocking the neonatal Fc receptor. Dr. Gil Wolfe explains how it compares to other treatment options like corticosteroids, taking side effects and quality of life into consideration. Dr. Wolf is a SUNY Distinguished Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences.
Guest: Nicholas J. Silvestri, MD
FcRn inhibitors provide a targeted approach to generalized myasthenia gravis (gMG) treatment by reducing pathogenic antibodies. These therapies offer fewer side effects compared to traditional treatments like corticosteroids, improving both disease control and quality of life. Dr. Nick Silvestri, a Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences, explains this treatment’s potential.
Guest: Henry Kaminski, MD
Generalized myasthenia gravis (gMG) is a complex autoimmune disease with a wide range of symptoms, from ocular issues to severe muscle weakness. As our understanding of the pathophysiology behind gMG evolves, so does our ability to improve patient management. Join Dr. Henry Kaminski as he examines emerging advancements in gMG treatment, including FcRN inhibitors and immune-targeting therapies. Dr. Kaminski is the Meta A. Neumann Professor of Neurology at the George Washington University School of Medicine and Health Sciences.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: B. Joy Snider, MD, PhD
Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). "Time Out: A Case-Based Deep Dive into the Challenges of ARIA Management" is an educational program designed to enhance clinicians' practical skills through the examination of complex, real-world case scenarios. This interactive program equips all members of the multidisciplinary care team with effective strategies for acute ARIA management, fostering confidence in handling intricate emergency situations. Join our expert panel to deepen your expertise and contribute meaningfully to patient care in the evolving landscape of ARIA.
Host: James R. Bateman, MD, MPH
Guest: Jerome A. Barakos, MD
Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM
Guest: B. Joy Snider, MD, PhD
Guest: Charles P. Vega, MD
Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with in-depth knowledge and practical skills for effective ARIA management. Featuring the latest advances in anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs), this educational format aims to prepare participants for real-world scenarios. Join our panel of expert faculty in this essential session to enhance team-based strategies and optimize patient outcomes.
Guest: Kelly G. Gwathmey, MD
ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an average of two months sooner. Here to talk about this work is Dr. Kelly Gwathmey, Professor of Neurology at the Virginia Commonwealth University School of Medicine who presented a session on this topic at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting.
Guest: John F. Brandsema, MD
As patients with Duchenne muscular dystrophy (DMD) age, their treatment regimens, considerations, and goals change. That’s why Dr. John Brandsema is here to talk about how we can best treat and support patients with DMD throughout their entire care journey. Dr. Brandsema is the Neuromuscular Section Head at the Children’s Hospital of Philadelphia.
Guest: John F. Brandsema, MD
Between 60 and 70 percent of patients with Duchenne muscular dystrophy (DMD) also have a diagnosable neurobehavioral phenotype like autism, ADHD, and anxiety. Here to talk about these common neurobehavioral issues in patients with DMD and how we can manage them is Dr. John Brandsema, Neuromuscular Section Head at the Children’s Hospital of Philadelphia.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John F. Brandsema, MD
The gene therapy delandistrogene moxeparvovec was recently approved for patients with Duchenne muscular dystrophy (DMD) who are at least 4 years old. This expanded approval is based on the efficacy and safety results from the EMBARK trial. Joining Dr. Charles Turck to break down those key findings and the implications of this advancement in DMD treatment is Dr. John Brandsema. Dr. Brandsema is the Neuromuscular Section Head at the Children’s Hospital of Philadelphia, where one of the clinical trials for this gene therapy took place.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jasmohan Bajaj, MD
Around 50 percent of people with cirrhosis have hepatic encephalopathy, which means some kind of brain dysfunction. As these patients age, it gets more and more difficult to differentiate between hepatic encephalopathy and dementia, which is why two recent studies sought to uncover how many patients with dementia have undiagnosed cirrhosis. According to the findings, the rate of undiagnosed cirrhosis and hepatic encephalopathy could be as high as 10‒13 percent. Joining Dr. Charles Turck to share further details about the studies, findings, and implications is Dr. Jasmohan Bajaj, Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dr. Robert J. Shmookler Reis, PhD
Guest: Dr. Srinivas Ayyadevara, PhD
Numerous factors could predispose patients to the progression of mild cognitive impairment or dementia and Alzheimer’s disease. Fortunately, a recent study found that a cholesterol-lowering medication called ezetimibe might help reduce the risk of Alzheimer’s disease progression and related dementias. To learn about the methods and key findings of the study, join Dr. Charles Turck as he takes a deep dive with Dr. Robert Reis, Professor and Researcher at the University of Arkansas for Medical Sciences’ Institute on Aging College of Medicine and Research Career Scientist at the Central Arkansas Veterans Healthcare System’s Geriatric Research, Education and Clinical Center, and Dr. Srini Ayyadevara, Associate Professor at the UAMS Institute on Aging College of Medicine and is a Research Health Scientist at the Central Arkansas VA’s GREC Center.
Host: Ashley Baker, MSN, PMHNP
Guest: Istvan Mody, PhD
The objective of this study around Alzheimer’s disease was to enhance oscillations in laying down memory traces and cognition. Using mice, the human APOE 4 gene was inserted into them, so they replicated similar events that take place in Alzheimer’s patients, and other mice were treated with DDL-920. The hope is to move on to human patients and to have a big impact on improving Alzheimer’s patient's life, cognition, and memory. To learn more, join Psychiatric Nurse Practitioner Ashley Baker as she speaks with Dr. Istvan Mody, Professor of Neurology and Physiology at UCLA Health and recipient of the J. Allyn Taylor International Prize in Medicine in 2018.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nadia Merchant, MD
Guest: Melody Shi, MD
Guest: Despoina Galetaki, MD
Steroids are one of the main treatments for patients with Duchenne muscular dystrophy (DMD), but prolonged steroid use can come with many endocrine side effects, like weight gain, insulin resistance, and adrenal insufficiency. To learn more about these endocrine complications and surveillance, a recent survey was conducted, and here to share the results with Dr. Charles Turck are study authors Drs. Nadia Merchant, Melody Shi, and Despoina Galetaki.
Guest: Mar Tintore, MD
At this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, learn about a presentation on the new criteria for diagnosing multiple sclerosis (MS) patients with Dr. Mar Tintoré, President of ECTRIMS and Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain.
Guest: Mar Tintore, MD
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 annual meeting is celebrating its 40th anniversary in Copenhagen, Denmark. 9,000 delegates from all over the world are expected to attend this multiday event, which will include keynote lectures, poster sessions, and selected scientific and educational sessions, as well as plenty of philanthropic and networking opportunities and more. Tune in for a brief overview with Dr. Mar Tintoré, President of ECTRIMS and Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain.
Host: Ashley Baker, MSN, PMHNP
Guest: Kathleen Nadeau, PhD
Girls and women with ADHD are often underdiagnosed and undertreated compared to boys and men, which puts them at risk of serious issues like unplanned pregnancies, cigarette smoking, and even anxiety and depression. To help us better identify and manage girls and women with ADHD, psychiatric nurse practitioner Ashley Baker speaks with Dr. Kathleen Nadeau, Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.
Guest: Kathleen Nadeau, PhD
It’s important to be aware of the different ways ADHD impacts girls and women compared to boys and men, which is why Dr. Kathleen Nadeau is here to help shed light on those differences. Dr. Nadeau is the Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kay Davies, PhD, DBE FMedSci FRS
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by the progressive loss of muscle, and it primarily occurs in young boys. And since there’s currently no cure, recent therapeutic advancements are aimed at improving symptoms and patient’s quality of life. Dive in to review the therapeutic landscape with Dr. Charles Turck as he’s joined by Dr. Kay Davies, who’sDr Lee's Professor of Anatomy Emeritus at the University of Oxford.
Host: Craig M. McDonald, MD
Guest: Crystal Proud, MD
Guest: Aravindhan Veerapandiyan, MD
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
Host: Ashley Baker, MSN, PMHNP
Guest: David Goodman, MD, LFAPA
ADHD is a lifelong disorder, but its symptoms like memory and concentration difficulties can often be misinterpreted as normal functions of aging. So to help address this misunderstanding, psychiatric nurse practitioner Ashley Baker speaks with Dr. David Goodman about essential diagnostic and treatment strategies for older adults with ADHD. Dr. Goodman is the Director of the Adult Attention Deficit Disorder Center of Maryland.
Host: Ashley Baker, MSN, PMHNP
Guest: Timothy Wilens, M.D.
The treatment journey for ADHD typically begins in childhood, but therapy interventions must be modified as our patients transition into adulthood. So how do we support our patients along this continuum? Tune in for a discussion on ADHD treatments and the difficulties that result in a missed pediatric diagnosis with psychiatric nurse practitioner Ashley Baker and Dr. Timothy Wilens, Chief of the Division of Child and Adult Psychiatry at Massachusetts General Hospital and a Professor of Psychiatry at Harvard Medical School.
Host: Karima Benameur, MD
According to recent data, nutrition plans like the Mediterranean, DASH, and MIND diets can help patients with a variety of neurological diseases, including multiple sclerosis, stroke, and dementia. Tune in to hear Dr. Karima Benameur discuss this research and how we can counsel patients with neurological diseases about nutrition. Dr. Karima Benameur is an Associate Professor of Neurology at Emory University who presented a session on this topic at the 2024 American Academy of Neurology Annual Meeting.
Host: Ashley Baker, MSN, PMHNP
Guest: Stoni Johnston, APRN, MSN, PMHNP-BC
Insomnia is one of the common issues HCPs see in patients with ADHD, and narcolepsy can also have similar presentations of ADHD. So how can we accurately diagnose ADHD from a sleep disorder? Dive in as Psychiatric Nurse Practitioner Ashley Baker is joined by Stoni Johnston, Psychiatric Nurse Practitioner and Founder of Sulcata Psychiatry in Tomball, Texas.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lauren Treat, MD
Guest: Wendy Gaultney, MD
Children who have neurological disorders and experience pain are often not able to articulate how their pain affects them. That’s why it’s important for clinicians to understand the brain’s role in the experience of pain and how to help these patients and their families navigate their pain. Joining Dr. Charles Turck to share best practices for counseling and treating pain in children with neurological disorders are Drs. Lauren Treat and Wendy Gaultney, who presented a session on this topic at the 2024 American Academy of Neurology Annual Meeting.
Host: Ashley Baker, MSN, PMHNP
Guest: Margaret Sibley, PhD
In the years following the COVID-19 pandemic, clinicians saw the biggest increase in patients 25 years and older seeking help for ADHD. And even though healthcare providers aren’t entirely sure where this trend came from, research shows that a lot of ADHD care went to telehealth during this time and advertisements from startup companies generating profit off of prescribing ADHD medications were hitting people on social media. So to dive into insights for providing these patients with good information, Psychiatric Nurse Practitioner Ashley Baker is joined by Dr. Margaret Sibley, Licensed Clinical Psychologist and Professor of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine.
Guest: Monica Maria Diaz, M.D., M.S.
Climate change can have devastating effects on neurologic infections. One study suggested that the more population-dense urban areas are, the more likely several infections can be transmitted between humans. So what can be done to reduce this risk? Tune in with Dr. Monica Maria Diaz, Assistant Professor of Neurology at the University of North Carolina School of Medicine. This is also the topic of her session at the 2024 American Academy of Neurology Annual Meeting.
Guest: Erick Tarula, MD
Many complications can occur in hospitalized neurological patients from an internal medicine standpoint. So a session from the 2024 Academy of American Neurology (AAN) Annual Meeting focused on these common issues, how they can be addressed quickly, and the role of a neurohospitalist. Dive in further with Dr. Erick Tarula, Assistant Professor in the Department of Neurology at the University of Wisconsin School of Medicine and Public Health.
Host: Eliza C. Miller, MD
Stroke is one of the leading causes of death in pregnancy in the United States, underscoring the importance of knowing the causes, risks, and treatment of stroke in pregnancy and postpartum. That’s why Dr. Eliza Miller is here to share key insights from her session at the 2024 AAN Annual Meeting that focused on this exact topic. Dr. Miller is an Associate Professor of Neurology in the Division of Stroke and Cerebrovascular Disease at Columbia University.
Host: Michele Longo, MD
Medical gaslighting refers to the situation where a medical professional disregards an individual's health concerns. It most often affects patients suffering from neurological disorders like long COVID and MS, and it can be extremely damaging to the physician-patient relationship. This underscores the importance of knowing how to recognize and reduce medical gaslighting in clinical practice, which is why Dr. Michele Longo is here to discuss the “Healing Doubt: Confronting and Overcoming Medical Gaslighting” session she presented at the 2024 AAN Annual Meeting.
Host: Ashley Baker, MSN, PMHNP
Guest: Nabil Ali, MD
When it comes to treating patients with schizophrenia, it’s important to remember to not have one particular medication that you stick by at all times and to consider things like their personal history and their side effects. To learn more about the treatment algorithm when managing these patients, join in with Psychiatric Nurse Practitioner Ashley Baker as she speaks with Dr. Nabil Ali, Assistant Consulting Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine in Durham, North Carolina.
Host: Ashley Baker, MSN, PMHNP
Guest: Lauren Walker, OT
Occupational therapists (OT) play a crucial role in the management of schizophrenia by focusing on enhancing the patient’s ability to engage in meaningful activities and daily life tasks. Working towards a goal that a patient has by breaking it down into smaller parts is one of the ways to help a patient be successful and spark motivation. Dive in further on how OT’s assist patients through first-episode psychosis and subsequent life changes with Psychiatric Nurse Practitioner Ashley Baker as she speaks with Lauren Walker, Occupational Therapist at Northwestern Feinberg School of Medicine.
Host: Ashley Baker, MSN, PMHNP
Guest: Amber Salter, PhD
In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Victoria Leavitt, PhD
Disease-modifying therapies (DMTs) are an effective option for patients with multiple sclerosis (MS). In fact, a recent study presented at the 2023 joint ECTRIMS-ACTRIMS meeting in Italy found that MS patients being treated with a DMT had better cognitive function than those who were not. However, the same study also found that women are less likely than men to receive DMT treatment. Dive further into the findings with Dr. Andrew Wilner and Dr. Victoria Leavitt, Assistant Professor of Neuropsychology at Columbia University.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Dejan Jakimovski, MD, PhD
Despite the fact that categorial scores like the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS) are considered to be the gold standard, a recent study found that the Scripps Neurological Rating Scale (SNRS) and the Combinatorial Weight-Adjusted Disability Score (CombiWISE) may be better suited for assessing disability in patients who are severely affected by MS. Learn more about this study’s findings with Dr. Andrew Wilner and Dr. Dejan Jakimovski, a Research Assistant Professor in the Department of Neurology at the University of Buffalo who presented this research at the joint 2023 ECTRIMS-ACTRIMS meeting.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Ahmed Zayed Obeidat, MD, PhD
Guest: Lauren Beranek, BS
Polypharmacy is defined as the regular use of five or more prescribed medications, and due to their disease course, related symptoms, and side effects, patients with multiple sclerosis are at an increased risk of polypharmacy. So to hear insights on ways to identify, manage, and prevent polypharmacy, Dr. Mary Catherine Cheeley is joined by Dr. Ahmed Obeidat, Associate Professor of Neurology, and Lauren Beranek, MD candidate at the Medical College of Wisconsin.
Find a full article on their findings published in Practical Neurology.
Host: Ashley Baker, MSN, PMHNP
Guest: Samuel Dienel, PhD
Using postmortem brain tissue, a recent study investigated how alterations in somatostatin messenger RNA levels in the dorsolateral prefrontal cortex affect cognition among individuals with schizophrenia, bipolar disorder, and major depressive disorder. Dive into the findings with psychiatric nurse practitioner Ashley Baker and Dr. Samuel Dienel, a student in the Medical Scientist Training Program at the University of Pittsburgh.
Host: Ashley Baker, MSN, PMHNP
Guest: Stanley N. Caroff, MD
Catatonia is a neuropsychiatric condition characterized by disturbances in psychomotor function, stemming from various disorders impacting brain function. And while catatonia is not specifically related to schizophrenia alone, it’s important to know how to recognize and treat schizophrenic patients with catatonic symptoms. That’s why psychiatric nurse practitioner Ashley Baker speaks with Dr. Stanley Caroff about his research focusing on the management of schizophrenia with catatonic symptoms. Dr. Caroff is an Emeritus Professor of Psychiatry at the University of Pennsylvania Perelman School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jagan Pillai, MD, PhD
Cerebral amyloid angiopathy (CAA) is a common neurological change that frequently coexists with other pathologies like Alzheimer's disease and Lewy body dementia, which led a team of researchers to investigate the risk factors and prevalence of CAA. The study found that not only is age a risk factor for CAA, but CAA is also seen in patients with Lewy body pathology alone and in patients with both Alzheimer's disease and Lewy body pathology. Dive further into the findings with Dr. Charles Turck and Dr. Jagan Pillai, a behavioral neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health.
Guest: Nancy Chiaravalloti, PhD
Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.
Host: Ashley Baker, MSN, PMHNP
Guest: Anna Shah, MD
The prevalence of multiple sclerosis seems to be increasing in patients, and the majority of those patients are diagnosed with MS around the peak family planning age. So family planning should be an integral part of comprehensive patient-centered MS care. Learn more with Psychiatric Nurse Practitioner Ashey Baker as she speaks with Dr. Anna Shah, Assistant Professor of Neurology and the Director of Neurology Outpatient Patient Safety & Experience at the University of Colorado Anschutz School of Medicine.
Guest: Daniel Harrison, MD
Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.
Guest: Robert Motl, PhD
Rehabilitation training for multiple sclerosis patients aims to improve mobility, cognitive function, and quality of life. But one of the largest barriers to having more high-quality randomized control trials of rehabilitation in MS is that most researchers could not be following a stage of different research approaches. So addressing the unmet needs in rehabilitation research is needed to make MS interventions more powerful. You’ll learn more in this episode with Dr. Robert Motl, Professor in the Department of Kinesiology and Nutrition with a secondary appointment in the Department of Rehabilitation Sciences at the University of Illinois Chicago.
Guest: Marisa McGinley, DO
The amount of patients being diagnosed with neurological conditions and multiple sclerosis (MS) is a growing number, which causes a need for more neurologists, MS specialists, and better access to care. A potential advantage of using technology in MS care would be to break down the geographic barrier. To learn more about telehealth in MS care, tune in with Dr. Marisa McGinley, Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, who also presented this topic at the ACTRIMS Forum 2024.
Guest: Yinan Zhang, MD
Chronological age is the biggest early driver of disease progression in patients with multiple sclerosis (MS). That’s why a team of researchers wanted to explore whether biomarkers like p16 and the epigenetic clock can be used to assess biological aging in patients with MS. They found that while patients with MS are aging faster than people without MS based on the epigenetic clock biomarker, no chronological age correlation in p16 expression has been identified in patients with MS. Dive further into these findings with Dr. Yinan Zhang, an Assistant Professor of Neurology at Ohio State University who presented this research at the 2024 ACTRIMS Forum.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Marcus E. Peter, PhD
Death induced by survival gene elimination (DISE) is a cell death mechanism mediated by short RNAs. And according to a recent study, there may be a correlation between toxic DISE, DNA damage, and neuronal cell death in patients with Alzheimer’s disease. Learn more about the study’s findings and potential implications with Dr. Andrew Wilner and Dr. Marcus Peter, Professor of Medicine in the Division of Hematology and Oncology as well as a Professor of Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine in Chicago.
Host: Ashley Baker, MSN, PMHNP
Guest: Morris Goldman, MD
Guest: Dara Sanandaji
A diagnosis of schizophrenia can be distressing, making clinical interventions crucial for both the patient and their family. With the assistance of an appropriate treatment plan and peer support, the patient can gain empowerment to take control of their life and pursue long-term goals. Joining Psychiatric Nurse Practitioner Ashley Baker to discuss next steps following a schizophrenia diagnosis is Dr. Morris Goldman, Associate Professor of Psychiatry at Northwestern Feinberg School of Medicine, and Dara Sanandaji, Peer Support Supervisor at the Recovery from Early Psychosis Program.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: George Bloom, PhD
Toxic tau protein refers to an aberrant form of the tau protein in the brain, commonly associated with Alzheimer's disease, where it forms tangles and disrupts normal cellular function, which contributes to cognitive decline and neuronal damage. To learn more about the role of toxic tau proteins in Alzheimer’s disease, tune in to hear Dr. Andrew Wilner speak with Dr. George Bloom, Professor of Biology, Cell Biology, and Neuroscience at the University of Virginia.
Guest: J. William Lindsey
Epstein-Barr virus (EBV) has long been associated with multiple sclerosis (MS), but a recent study from UTHealth Houston has shed light on its role in the development of MS. To learn more on what we know about EBV-specific T-cells, join Dr. J. William Lindsey, Senior Author of the study, titled UTHealth Houston Study: EBV-specific T-cells play key role in development of multiple sclerosis, and Professor in the Department of Neurology and Director of the Division of Multiple Sclerosis and Neuroimmunology with McGovern Medical School at UTHealth Houston.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stefano Pluchino, MD, PhD
An international collaborative phase 1 study has shown that the injection of a specific form of stem cells into the brains of patients with progressive multiple sclerosis is safe and effective in preventing further brain damage. However, a different type of clinical trial is needed to address whether an advanced cell therapy made of brain-specific stem cells is indeed leading to amelioration of disease features. Take a deeper look into the findings from this study as Dr. Charles Turck speaks with the author of the study, Dr. Stefano Pluchino, Professor of Regenerative Neuroimmunology and Honorary Consultant in Neurology in the Department of Clinical Neurosciences at Cambridge University.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Marc Haut, PhD
A recent phase 1 study investigated the safety and feasibility of combining focused ultrasound and aducanumab, which is a monoclonal antibody for amyloid, to open the blood-brain barrier in patients with Alzheimer's disease. And what the researchers found was about a 50 percent overall reduction of cerebral amyloid-beta load in the target areas compared to the untreated areas. Dive further into these findings and next steps in this line of research that may impact the way we treat Alzheimer’s disease with Dr. Andrew Wilner and Dr. Marc Haut, Director of the Rockefeller Neuroscience Institute’s Memory Health Clinic at West Virginia University.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jini Naidoo, PhD
According to new research featured in Aging Biology, a treatment involving 4-phenylubrate (PBA) may delay or reverse signs of Alzheimer’s disease. To learn more, Dr. Andrew Wilner dives into the results and potential implications of this mouse-model study with Dr. Jini Naidoo, Research Associate Professor of Sleep Medicine at the Perelman School of Medicine at the University of Pennsylvania.
Host: Ashley Baker, MSN, PMHNP
Guest: Hannah Brown, MD
Unfortunately, when it comes to the diagnosis and treatment of schizophrenia, there is nothing to definitively give clinicians a diagnosis, so it’s important to have a clinical evaluation and rule out everything else. But once a first episode psychosis diagnosis has been made, what treatment options are available? Dive into this episode with Psychiatric Nurse Practitioner Ashley Baker who is joined by Dr. Hannah Brown, Director of the Wellness and Recovery After Psychosis Program at Boston Medical Center and Assistant Professor of Psychiatry at Boston University Chobanian and Avedisian School of Medicine.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: William A. Kilgo, MD
According to new research featured at the joint ECTRIMS-ACTRIMS meeting, the Multiple Sclerosis Disease Activity (MSDA) Test is a reliable indicator of recent objective disease activity when used within an academic clinic. Based on these findings, Dr. Andrew Wilner sits down with lead author of the study, Dr. William Kilgo, to discuss how the MSDA can be applied in our real-world clinical practice.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Carri Polick, PhD, RN
Two recent studies linked childhood stress and stressors experienced across the lifespan to the severity of multiple sclerosis (MS) symptoms. In fact, both childhood and adult stressors were associated with MS disability and the so-called invisible symptoms of pain interference and psychiatric morbidity while only adult stressors were related to relapse burden. Joining Dr. Andrew Wilner to discuss these findings and how they may shift our approach to caring for patients with MS is Dr. Carri Polick, a postdoctoral fellow and VA scholar in the Duke National Clinician Scholars Program.
Host: Jennifer Caudle, DO
Guest: Mitzi Joi Williams, MD, FAAN
The CHIMES trial is the first phase IV clinical trial focusing exclusively on Black and Hispanics living with multiple sclerosis (MS). Not only did this study reveal key details about the disease burden of MS in this patient population, but it also provides an example of how the cycle of health inequity in research efforts can be broken. Learn more with Dr. Jennifer Caudle and the lead investigator of the CHIMES trial, Dr. Mitzi Joi Williams.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Anibal Chertcoff, MD
According to a recent study, psychiatric conditions like depression, anxiety, bipolar disorder, and schizophrenia may be early indicators of multiple sclerosis (MS) years before symptoms appear, which could enable the early diagnosis and treatment of patients with MS. Joining Dr. Charles Turck to share key details and findings from this study is Dr. Anibal Chertcoff. Not only is Dr. Chertcoff the lead author of the study, but he’s also a postdoctoral fellow at the University of British Columbia where his research centers on characterizing the multiple sclerosis prodrome.
Guest: Ahmed Abdelhak, MD
The state of research to better detect multiple sclerosis activity is changing rapidly, with emerging assays and other tools seeking to predict the occurrence of MRI lesions or relapses in patients. To dive into the latest biomarker research for MS in children, tune in with Dr. Ahmed Abdelhak, Clinical Instructor of Neurology at the University of California San Francisco School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Tirisham Gyang, MD
Guest: Gopika Govindan Kutty, MD
In past studies, it was seen that multiple sclerosis was more prevalent in White individuals from Northern European ancestry. However, more recent data is showing that MS can happen in anyone and everyone, and there may be slight clinical variations in the disease when we look at different demographic populations. So how can we better serve minority communities? To dive in further, Dr. Charles Turck is joined by Dr. Tirisham Gyang, Clinical Assistant Professor of Neurology at the Ohio State University School of Medicine, and Dr. Gopika Kutty, Neurologist at the University of Pittsburgh Medical Center.
Read their publication, titled “Disparities in Multiple Sclerosis: Incorporating Equity into Clinical Care and Research,” which was published on Practical Neurology in July 2023.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jay Avasarala, MD, PhD
The three disease-modifying therapies for MS added into the World Health Organization’s (WHO) Essential Medicines list is a great step forward for patients afflicted with this chronic disease and could also serve as a model for other neurological disorders. Dive in as Dr. Charles Turck talks to one member of the team who was responsible for submitting this list of medications, Dr. Jay Avasarala, Director of Comprehensive Care Center for Multiple Sclerosis and Neuroimmunology at the Kentucky Neuroscience Institute in Lexington.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Craig Chepke, MD, FAPA
From a women's mental health pre-conference to new mechanisms of action coming into psychiatry for the first time in decades, there’s a lot to look forward to at this year’s meeting. Join Dr. Mary Katherine Cheeley as she gets more highlights from Dr. Craig Chepke, Medical Director of Excel Psychiatric Associates and Psych Congress 2023 Scientific Advisor.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Eoin Flanagan, MB, BCh
For the first time since 2008, the International Advisory Committee on Clinical Trials in Multiple Sclerosis have made updates to their diagnostic guidelines for patients with suspected multiple sclerosis (MS). Joining Dr. Andrew Wilner to discuss these key updates is Dr. Eoin Flanagan, the Chair of the Division of Multiple Sclerosis and Autoimmune Neurology at the Mayo Clinic in Rochester, Minnesota.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: John Corboy, MD, MA
Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado.
Guest: Sergio Baranzini, PhD
A recent study was designed by the International Multiple Sclerosis Genetics Consortium with the goal in mind to find out whether the severity of multiple sclerosis (MS) could be influenced by genetics. Dive in with Dr. Sergio Baranzini, Distinguished Professor of Neurology at the University of California San Fransico and Co-Senior Author of the study.
Host: Jerome Lisk, MD
Guest: Santosh Kumar, PhD
In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Ashley Baker, MSN, PMHNP
Before COVID-19, HCPs and patients had a lot of access to virtual healthcare, but it wasn’t being fully utilized. So what should we know about the ongoing use of telemedicine and the Ryan Haight Act? Take a deep dive with Dr. Mary Katherine Cheeley as she speaks with Ashley Baker, Psychiatric Nurse Practitioner and Co-Founder of Ascend Integrative Medicine in Boston, MA.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Avindra Nath, MD
Researchers from the National Institutes of Health (NIH) found that 100 percent of the participants in this study had fatigue and experienced cognitive difficulties. So what can we learn from this new research to help us diagnose and treat patients with disabling neurological symptoms after they had COVID-19? To discuss the findings, Dr. Charles Turck is joined by Dr. Avindra Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke.
Host: Jennifer Caudle, DO
Guest: John F. Brandsema, MD
Guest: Vamshi K. Rao, MD
Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Because LGMD is so variable, it can be hard to detect and there are no FDA-approved treatments currently. Advances in gene transfer therapy have been slow to emerge. However, helping clinicians detect LGMD and know the next best steps is critical to effective management of LGMD, along with identifying patients for clinical trials.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Julie Parsons, MD
Guest: Craig Zaidman, MD
Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lokesh Shahani, MD, PhD, MPH, FACP, FASAM
Due to their clinical overlap, distinguishing between neurocognitive and psychiatric disorders can be challenging, but an accurate diagnosis is crucial for timely assessment and treatment. Find out how we can better identify and treat complex neurocognitive disorders such as Alzheimer's disease and other forms of dementia with Dr. Charles Turck and Dr. Lokesh Shahani, Associate Professor of Psychiatry and Behavioral Sciences at UT Health Houston McGovern Medical School who presented on this exact topic at the 2023 APA Annual Meeting.
Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA
Behavioral and psychological symptoms of dementia (BPSD) refers to a group of noncognitive symptoms that commonly occur in patients with dementia. While data shows efficacy for treatment modalities for these symptoms and behaviors, the use of psychotropic medications has been met with controversy due to their adverse effects. Tune in to hear Dr. Rajesh Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine, discuss how we can address those controversies while providing optimal care for our patients, which was the focus of his presentation at the 2023 American Psychiatric Association Annual Meeting.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Dominique Higgins, MD, PhD
Glioblastoma is the most common type of brain tumor while also being one of the most aggressive cancers in adults. So what do we need to know about ferroptosis? Dive in with Dr. Andrew Wilner as he’s joined by Dr. Dominique Higgins, Assistant Professor of Neurosurgery at the University of North Carolina School of Medicine.
Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA
Here to share some of the key presentations at the 2023 American Psychiatric Association (APA) Annual Meeting is Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.
Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA
Find out what previous and ongoing clinical trials are telling us about the use of cannabinoids to treat behavioral and psychological symptoms of dementia (BPSD) with Dr. Jerome Lisk and Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Selim Benbadis, MD
It may be challenging for a family member to take a video on their cell phone while a patient is having a seizure. However, they have been deemed useful in helping physicians establish a history of seizures in epileptic patients. So should clinicians consider this as a reimbursable diagnostic tool? Joined by the physician who posed this question in a recent article for the journal Neurology Clinical Practice, Dr. Andrew Wilner speaks with Dr. Selim Benbadis, Professor of Neurology and the Director of the Comprehensive Epilepsy Program at the University of South Florida.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Nassim Rad, MD
Guest: Vanessa Battista, RN
Collaborative care plays an important role in treating patients is spinal muscular dystrophy (SMA). To learn more about this, Dr. Andrew N. Wilner is joined by Drs. Vanessa Battista and Nassim Rad to share their insights on team structures and collaborative care for SMA.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John F. Brandsema, MD
Spinal muscular atrophy (SMA) is a rapidly progressive disease, but current treatment options might help us slow its progression. Dr. Charles Turck explores these treatment options with Dr. John Brandsema from the Perelman School of Medicine at the University of Pennsylvania.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: David Weisman, MD
Alzheimer’s disease is the most common form of dementia, and symptoms become more severe over time. In fact, it’s the leading cause of disability and poor health in older adults. And although there’s no cure, a new medication called lecanemab recently received accelerated approval by the US Food and Drug Administration. So what might this new development mean for the 6 million Americans living with this debilitating disease? Find out as Dr. Andrew Wilner speaks with fellow ReachMD host Dr. David Weisman, who’s also the Director of Clinical Research at Abington Neurological Associates.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Marilyn J. Wooley PhD
Due to the nature of their work, first responders may be at a higher risk for developing posttraumatic stress disorder (PTSD). So how can clinicians help their front-line patients with PTSD? Dr. Andrew Wilner will discuss this with Dr. Marilyn Wooley, Clinical Psychologist who specializes in treating first responders and author of the book, How Heroes Heal: Stories of First Responders and the Journey from Posttraumatic Stress Injury to Posttraumatic Growth.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Bruce Hermann, PhD
Guest: Shlomo Shinnar, M.D., Ph.D.
In hopes of learning more about how the brain changes due to aging in patients with childhood-onset epilepsy, a new study was funded that may suggest some interesting findings. So what do we need to know from the results of this study? To dive into this topic, Dr. Andrew Wilner is joined by Dr. Bruce Hermann, Emeritus Professor at the University of Wisconsin School of Medicine and Public Health, and Dr. Shlomo Shinnar, Professor Emeritus of Neurology and Pediatrics at Albert Einstein College of Medicine.
Host: Jerome Lisk, MD
Guest: Katherine Longardner, MD
A recent five-year observational study aimed to determine the impact of individual autonomic domains that were associated with Parkinson’s disease. So what were the key findings of this study? Join Dr. Jerome Lisk as he welcomes Dr. Katherine Longardner, Assistant Professor of Neurosciences at UC San Diego Health, to discuss this trial in-depth.
Guest: Matt Birnholz, MD
Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract.
To review the full abstract, please click here.
Host: Jose Rubio, MD
If clinicians can better understand the pathophysiology of schizophrenia, it could lead to more therapeutic options for this illness. So which potential mechanisms could be involved in its pathophysiology and in the discovery of more treatments for schizophrenia? Learn more about this illness with Dr. Jose Rubio, Assistant Professor at the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Philip D. Harvey, PhD
The current therapies we have available for schizophrenia are very effective at reducing psychotic symptoms in most patients, but for about 30 percent of patients, adverse events and suboptimal treatment responses can take a heavy toll. Could emerging therapies help us address these unmet needs? Learn more about the efficacy and tolerability limitations of current treatment options and what’s on the horizon with Dr. Charles Turck and Dr. Philip Harvey from the University of Miami Miller School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Craig Chepke, MD, FAPA
Trace amine-associated receptor type 1 (TAAR1) is thought to be the most important receptor for treating neuropsychiatric disorders, and it could provide more benefits and medications to patients with these illnesses. To discover more, Dr. Charles Turck, is joined by Dr. Craig Chepke, Clinical Assistant Professor of Psychiatry at SUNY Upstate Medical University.
Host: Brian Barry
Guest: Amos Katz
Meet Susan and Mary, two real-world patients with different manifestations of progression in their RMS who were treated with the therapy option MAYZENT. So why was MAYZENT the appropriate choice for these patients, and how did they get started on this treatment option? Here to walk us through these two real-world patient cases and their perspectives on RMS management are Dr. Brian Barry and Dr. Amos Katz.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Deborah L. Korn, PsyD
Eye movement desensitization and reprocessing (EMDR) therapy is an interactive psychotherapy used to relieve stress and reduce symptoms of trauma. It is most commonly associated with the treatment of posttraumatic stress disorder (PTSD). But can this therapy also treat other stress-related disorders? To go into further detail, Dr. Charles Turck is joined by Dr. Deborah Korn, a clinical psychologist in private practice in Cambridge, Massachusetts and co-author of the book titled Every Memory Deserves Respect: EMDR, the Proven Trauma Therapy with the Power to Heal.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sean Lawler, PhD
The STING protein is a novel treatment pathway for cancer. How might it affect our patients’ immune response to diseases such as brain cancer? Dr. Sean Lawler, an Associate Professor in the Department of Pathology and Laboratory Medicine at Brown University in Providence, Rhode Island. joins Dr. Andrew Wilner to explore the role of the STING pathway.
Guest: Benjamin Izar, MD
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Brain metastases are common in patients with advanced melanoma and are a leading cause of cancer-related death. However, little is known as to why melanoma spreads to the brain, but new research from Columbia University may provide some answers. To discuss this recent discovery, Dr. Andrew Wilner is joined by Dr. Benjamin Izar, Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Craig Chepke, MD, FAPA
Curious about how the 2022 Psych Congress came together? Tune in to hear Steering Committee member Dr. Craig Chepke give us a behind-the-scenes look at the conference. Dr. Chepke is also the Medical Director of Excel Psychiatric Associates.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jason Barton, MD, PhD, FRCP(C)
Prosopagnosia, also known as face blindness, is a rare cognitive disorder. Joining Dr. Andrew Wilner to share his insights on this condition is Dr. Jason Barton, a Professor of Neurology, Ophthalmology and Visual Sciences, and Psychology at the University of British Columbia in Vancouver, Canada.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sanjay Kumar, PhD
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy. Due to recent research from Florida State University, we might have a better understanding of the potential link between a specific protein and increased vulnerability to neurodegeneration among patients with this disorder. Dr. Andrew Wilner is joined by Dr. Sanjay Kumar, Professor of Biomedical Sciences and Neuroscience at Florida State University, to discuss this new discovery.
Host: Jerome Lisk, MD
Guest: Mark Mintz, MD
Recent developments in artificial intelligence (AI) technology have shown to aid with neurological disease diagnosis, risk stratification, treatment response, and more. So what are the newest AI applications? And perhaps even more importantly, what’s to come in the future? To find out the answer to these and other key questions, Dr. Jerome Lisk speaks with Dr. Mark Mintz, Chief Medical Officer and Founder of NeurAbilities Healthcare, to discuss emerging AI tools in the field of neurology.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Craig Chepke, MD, FAPA
Schizophrenia is a chronic mental disorder characterized by symptoms that negatively affect a patient’s mental and emotional behaviors. And although there are current treatment options including first and second-generation antipsychotics, treatment challenges still persist. That’s why Dr. Andrew Wilner speaks to psychiatrist Dr. Craig Chepke from Excel Psychiatric Associates to discuss clinical strategies that can help optimize outcomes for our patients.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Zachary Marcum, PharmD, PhD
Hypertension affects nearly half of adults in the United States and is associated with cognitive decline and dementia. A wide variety of antihypertensive medications are prescribed to millions of people to control blood pressure and prevent vascular dementia. Could it be that certain medications are better than others in preventing brain injury from chronic hypertension? Dr. Andrew Wilner is joined by Dr. Zachary Marcum, Associate Professor in the School of Pharmacy-University of Washington, to discuss his recent study investigating the association between certain hypertension medications and reduced cognitive impairment.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Chan, MD
Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple sclerosis (MS), but their exact role is unclear. Despite that uncertainty, B-cell depletion therapies have shown to ease symptoms, prevent relapses, and even slow the course of the disease. So how exactly do B-cell therapies work, and how do we know if they’re right for our patients? Joining Dr. Charles Turck to talk about the role of b-cell therapies for our MS patients is Dr. Andrew Chan.
Guest: Alessandro Didonna, PhD
Join us as examine the involvement of B cells in MS pathogenesis and the mechanisms that lead to B cell overactivation with Dr. Alessandro Didonna, Associate Professor of Neurology at UCSF Weill Institute for Neurosciences.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
Guest: Daniel George, MSc, PhD
Although there’s still no cure for Alzheimer’s disease, we’ve made great strides in understanding the tragic disease that affects more than 50 million people worldwide. So what are the latest updates in treating and alleviating this disease? To learn more about what’s new in Alzheimer’s disease research, Dr. Jerome Lisk speaks with Dr. Peter Whitehouse and Dr. Daniel George, co-authors of American Dementia: Brain Health in an Unhealthy Society.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Francesca Gilli, MS, PhD
What B-cell therapies are available for multiple sclerosis, and how do they fit into our treatment approach—in the context of the COVID-19 pandemic and beyond? Tune in to hear Dr. Charles Turck speak with Dr. Francesca Gilli about B-cell therapies.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
From therapeutic limitations to routes of administration, there’s a lot we need to keep in mind when selecting a treatment option for our patients with multiple sclerosis (MS). But it’s also just as important to consider patient-specific elements too, like their preferences and the socioeconomic factors affecting them. That’s why Dr. Ahmed Obeidat joins Dr. Hector Chapa to share these and other key treatment considerations in MS care.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
Unfortunately, not all of our patients with multiple sclerosis (MS) respond well to treatment. That’s why it’s critical to constantly assess their response to treatment and notice the signs that someone might be an efficacy-challenged patient. But what exactly are those signs, and how can you go about switching therapies? Joining Dr. Hector Chapa to share key strategies for managing efficacy-challenged patients with MS is Dr. Ahmed Obeidat.
Host: Jerome Lisk, MD
Guest: Ashok K. Shetty, PhD
Gulf War Illness is a chronic condition characterized by physiological and psychological symptoms, including cognitive dysfunction, memory problems, and depression. But what’s currently known about this debilitating condition that affects nearly 30 percent of Gulf War veterans? And how can we treat them? Find out with Dr. Jerome Lisk as he speaks with Dr. Ashok Shetty from Texas A&M University College of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Vikram V. Bhise, MD
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
When it comes to managing multiple sclerosis (MS), it’s important to keep the patient at the center of care by learning about their unique goals as well as the sociodemographic and socioeconomic factors affecting them. So how can we learn more about our patients, and once we do, what evidence-based management strategies are available to us? Joining Dr. Charles Turck to share how we can tailor treatment plans for our patients with MS are Dr. Vikram Bhise and certified assistive technology practitioner Ms. Patty Bobryk.
Host: Paul Doghramji, MD
Guest: Vikram V. Bhise, MD
Shared decision-making is essential when it comes to caring for patients with multiple sclerosis. But what does its utilization actually look like in practice? To find out, Dr. Paul Doghramji speaks with Dr. Vikram Bhise, who shares a patient case in multiple sclerosis care that demonstrates how we can incorporate shared decision-making in practice.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Cheryl Carcel, MD, PhD
Although research suggests that women have a similar stroke risk as men, a new analysis has found that a very small percentage of participants in clinical trials investigating stroke treatments are female. So why are women underrepresented in these clinical trials, and what can be done to reverse this troubling trend? Joining Dr. Andrew Wilner to discuss strategies to improve the representation of women in stroke trials is Dr. Cheryl Carcel, neurologist and senior research fellow at the George Institute of Global Health.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Margaret Chisolm, MD
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is the handbook traditionally used by healthcare professionals to guide the diagnosis of psychiatric conditions, but a number of psychiatrists advocate for the perspectives approach, which extends beyond the DSM model. So how exactly do these two models differ? And how might this newer approach impact our patients? Joining Dr. Charles Turck to answer those and other key questions on the perspectives approach to diagnosing and treating patients with mental illness is Dr. Margaret Chisolm, author of From Survive to Thrive: Living Your Best Life with Mental Illness.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jose Rubio, MD
Schizophrenia is rarely a single-episode illness. In fact, 8 out of 10 patients will experience a relapse of symptoms after initial treatment. So how can we help reduce the frequency of relapse—and even non-adherence—among our patients with schizophrenia? To find out, Dr. Andrew Wilner is joined by Dr. Jose Rubio, psychiatrist at Long Island Jewish Medical Center and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, to talk about the use of long-acting injectable (LAI) antipsychotics for schizophrenia treatment.
Host: Jennifer Caudle, DO
Guest: Vikram V. Bhise, MD
Pediatric multiple sclerosis (MS) occurs in more than 8,000 children in the United States alone, but there’s little data regarding these patients’ quality of life. That’s why Dr. Vikram Bhise recently conducted research to gain a better understanding of pediatric MS patients’ quality of life as they transition into adulthood. And now, Dr. Bhise joins Dr. Jennifer Caudle to share the results that were presented at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
A multidisciplinary approach to multiple sclerosis (MS) is becoming more and more integral in practice as research continues to emerge on its significance. That’s why physical therapist Ms. Patty Bobryk is here to debrief us on some highlights from the rehabilitation track at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) that focused on collaborative care.
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
The rehabilitation track at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) was filled with key updates regarding collaboration, nonpharmaceutical symptom management strategies, and more. And Ms. Patty Bobryk, a physical therapist at Yampa Valley Medical Center, is here to review those updates with us.
Host: Jerome Lisk, MD
Guest: Tissa Wijeratne MD PhD FRACP FRCP FAAN
Since the onset of the COVID-19 pandemic, researchers and clinicians alike have strived to address the mysteries surrounding the virus, including its long-term side effects on patients. So what we do need to know about the emerging syndrome pointing to COVID-19’s neurological and cognitive impacts? To find out, Dr. Jerome Lisk is joined by Dr. Tissa Wijeratne, the Director of the Department of Neurology and Stroke Services at the University of Melbourne, to talk about post-COVID-19 neurological syndrome.
Host: Jerome Lisk, MD
Guest: Shivashankar Othy, DVM, PhD
Despite the high prevalence of multiple sclerosis (MS), there’s still a lot we don’t know about this disease. One such area of uncertainty is in regard to how MS causes the immune system to become dysfunctional, but this knowledge is key as it could help us develop new treatment options. And now, we might be one step closer to discovering those treatments thanks to a recent study exploring specific T cells, and joining Dr. Jerome Lisk to discuss that study is Dr. Shiva Othy, a Project Scientist in the Department of Physiology and Biophysics at the University of California Irvine School of Medicine.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Nicola Cascella, MD
Although there’s currently no cure for schizophrenia, it can be managed with therapy and medication—for some patients, that is. In fact, up to one-half of patients with severe symptoms don’t respond to medication. So how are we to care for this large percentage of patients living with treatment-resistant schizophrenia? That’s the question Dr. Andrew Wilner asks Dr. Nicola Cascella, an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine who recently conducted a case study exploring the potential use of deep brain stimulation for patients with treatment-resistant schizophrenia.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Karen Keough, MD
Guest: Dawn S. Eliashiv, MD
Dr. Dawn Eliashiv of the University of California—Los Angeles and Dr. Karen Keough of the Child Neurology Consultants of Austin, Texas discuss using EPIDIOLEX® to treat patients 1 year of age or older with seizures associated with LGS, Dravet syndrome, or TSC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lauren Gluck, MD
Relapsing forms of multiple sclerosis can progress quickly and aggressively. What should our patients be looking out for? Dr. Charles Turck is joined by Dr. Lauren Gluck to discuss how we can help patients cope with progressing RMS.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Kornberg, MD, PhD
What does the patient journey in multiple sclerosis progression look like? Dr. Charles Turck is joined by Dr. Michael Kornberg to discuss the impact of early detection and share strategies to help manage the burden of this disease.
Host: Jennifer Caudle, DO
Guest: Iris (Vanessa) V. Marin Collazo, MD
What can we do better to recognize relapsing multiple sclerosis in our patients? Dr. Iris V. Marin Collazo joins Dr. Jennifer Caudle to discuss key signs of progression and critical clinical tools to help measure it.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Emily Louise Johnson, MD
According to recent estimates, between 150,000 and 450,000 transgender patients have epilepsy. And as that number is only expected to grow, Assistant Professor of Neurology at Johns Hopkins School of Medicine Dr. Emily Johnson shares key considerations for treating transgender patients with epilepsy.
Guest: Maheen Mausoof Adamson, PhD
Tune in to hear Dr. Maheen Mausoof Adamson, a Clinical Associate Professor of Neurosurgery at Stanford School of Medicine, discuss her study on mental health in women and how we can take a more targeted treatment approach.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Maheen Mausoof Adamson, PhD
Traumatic brain injury, or TBI, manifests differently in men and women. Here to explore these differences is Dr. Maheen Mausoof Adamson, a Clinical Associate Professor of Neurosurgery at Stanford School of Medicine, meets with Dr. Andrew Wilner to discuss traumatic brain injuries in female patients.
Host: David Weisman, MD
Guest: Elizabeth Finger, MD
Patients with frontotemporal dementia, or FTD, suffer from shortfalls in social and emotional behavior. But emerging research might help guide us in treating this disorder. Dr. David Weisman meets with Dr. Elizabeth Finger, a clinical neurologist and an Associate Professor of Neurology at Western University in Canada, to discuss her latest research on FTD.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Paller, PhD
Lucid dreaming is complex and remains a mystery to many neurologists, but emerging research suggests we may be able to communicate with dreamers in REM sleep. Dr. Andrew Wilner is joined by Dr. Ken Paller, Northwestern University's Director of the Cognitive Neuroscience program and the training program in the Neuroscience of Human Cognition, to discuss his recent research on communicating with lucid dreamers.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Bret Stetka, MD
What do we know about the progression of the human brain? Dr. Andrew Wilner meets with Science Journalist Dr. Bret Stetka to discuss his new book, “A History of the Human Brain: From the Sea Sponge to CRISPR, How Our Brain Evolved.”
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.
Host: Jerome Lisk, MD
Guest: Jerrold Vitek, MD, PhD
What is deep brain stimulation, and how is this technology helping patients with conditions like Parkinson's disease and epilepsy? Tune in to hear Dr. Jerome Lisk speak with Dr. Jerrold Vitek about current and future applications of this technology.
Host: Jerome Lisk, MD
Guest: Jerrold Vitek, MD, PhD
Deep brain stimulation, or DBS, is an emerging surgical procedure that may help to manage movement disorders such as Parkinson’s disease. Dr. Jerrold Vitek joins Dr. Jerome Lisk to share what is to be expected when a patient undergoes this type of procedure.
Host: David Weisman, MD
Guest: Adil Javed, MD PhD
How can providers help mitigate the symptoms of a disease a debilitating as multiple sclerosis? Dr. David Weisman examines management strategies for patients with multiple sclerosis with is Dr. Adil Javed, a board-certified neurologist and an Associate Professor of Neurology at the University of Chicago.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Most commonly associated with respiratory symptoms, COVID-19 infections have led to a myriad of neurological symptoms such as encephalopathy and stroke. Dr. Andrew Wilner joins Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, to discuss obstacles that neurologists have faced during the COVID-19 pandemic.
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
With no standard criteria available, how do we detect broken heart syndrome in our patients? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, shares what we should be looking for.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Although the impact of COVID-19 can be long-lasting, many have had similar effects, even if they aren’t diagnosed with the disease. Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, shares some insight on the neurological symptoms that patients with COVID-19 are facing.
Host: David Weisman, MD
Guest: Mijail D Serruya MD,PhD
Every 40 seconds: that’s how often someone in the United States has a stroke. And it’s not uncommon for many of these patients to experience impaired functionality for the rest of their lives. But now, thanks to the latest technology, could something that seems straight out of a science-fiction novel like brain-computer interfaces help us improve the aftereffects of a stroke? Joining Dr. David Weisman to discuss his research that sought to address that exact question is Dr. Mijail Serruya.
Host: David Weisman, MD
Guest: Mijail D Serruya MD,PhD
Thousands of Americans live with the debilitating aftereffects of stroke, such as arm and communication problems. This makes technological developments like brain-computer interfaces absolutely critical for stroke survivors, but some questions are beginning to arise regarding the ethics of this technology. So in order for us to fully pursue this advancement, it’s important that we address those ethical concerns, as Dr. Mijail Serruya explains.
Host: Jerome Lisk, MD
Guest: Eric Gantwerker, MD, MMSc, FACS
The rise of gaming in medical education has become a much bigger and faster-moving phenomenon than we may know. To find out more, Dr. Jerome Lisk is joined by Dr. Eric Gantwerker from Level EX, which develops video games that are designed to improve clinical decision-making skills. Together, they talk about the evolving role of video games in healthcare settings and why we may be pressing play sooner than we think.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Tyler, MD
Further complicating the COVID-19 pandemic is the emergence of viral variants. Dr. Ken Tyler from the University of Colorado School of Medicine shares with us what we know so far about the COVID-19 variants that are quickly spreading around the world.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Tyler, MD
To find out what we currently know about the neurological complications caused by COVID-19, Dr. Andrew Wilner speaks with Dr. Ken Tyler, Professor and Chair of the Department of Neurology at the University of Colorado School of Medicine.
Host: Jerome Lisk, MD
Guest: Anthony L. Fine, M.D
Recent advancements in the field of fetal neurology have equipped clinicians to detect neurological diseases before the child is even born. Dr. Jerome Lisk joins Dr. Anthony Fine, a pediatric neurologist and epileptologist at Mayo Clinic in Rochester, to discuss some of these advancements.
Host: Anthony Alessi, MD
Guest: Lynn Taylor, MD
Meningiomas were in the news this spring after actress Mary Tyler Moore had a tumor removed from her brain. Ninety percent of meningiomas are benign, many are asymptomatic, and some are so slow-growing they go undiagnosed. But many are discovered as an incidental finding in patients with headache. How do we treat patients diagnosed with meningiomas? Dr. Lynn Taylor, associate clinical professor at the University of Washington Medical School in Seattle, discusses with host Dr. Anthony Alessi the signs, risks, and surgical options for patients with meningiomas, which patients require treatment and how to involve patients in their treatment plan.
Host: Anthony Alessi, MD
Guest: Jeffrey Kutcher, MD
Most athletes' concussions are not the result of the kind of hits that NFL players take, but they still need to be taken very seriously. The American Academy of Neurology now recommends all athletes suspected of a concussion be removed from the field immediately. Dr. Jeffrey Kutcher, director of Michigan NeuroSport, the sports neurology program at the University of Michigan and chair of the American Academy of Neurology's sports neurology section, joins host Dr. Anthony Alessi to discuss changes in neurologists' philosophy toward concussion, who the new guidelines are aimed at and how to reach them, and what treatment will be like in the future.
Host: Anthony Alessi, MD
Guest: Vera Bril, MD
At least half of diabetic patients will experience neuropathy some time in their life, but many of these patients never discuss the painful condition with their doctor. When a patient does complain of burning or electric shock sensations in their feet and hands, how should they be treated? Dr. Vera Bril, professor of neurology at the University of Toronto, joins host Dr. Anthony Alessi to discuss the latest American Academy of Neurology guidelines on neuropathy pertaining to medications and controlling symptoms.
Host: Anthony Alessi, MD
Guest: Neil Busis, MD
Is there an app for helping your patients improve their health? In fact, there are many. Dr. Neil Busis, chief of the division of neurology, department of medicine, at University of Pittsburgh Medical Center Shadyside and Practice and Technology editor of AAN.com, talks with host Dr. Anthony Alessi about the latest mobile technologies used to monitor patient experiences with chronic neurological issues, such as migraines and epileptic seizures. They also discuss how even standard smartphone functions can be used to improve the health and medical care of patients, and why text messaging is changing healthcare around the world.
Host: Anthony Alessi, MD
Guest: Lisa Shulman
Would it be better for Parkinson's patients to meet with their doctor in a group setting? Group visits are among the the novel approaches being studied for Parkinson's patients. Dr. Lisa Shulman, professor of neurology and co-director of the Maryland Parkinson's Disease and Movement Disorders Center in Baltimore, joins host Dr. Anthony Alessi to discuss who might benefit from group visits, how it compares to traditional care, and the practical billing issues involved. They also discuss new research on treadmill walking in the treatment of patients with Parkinson's disease.
Host: Anthony Alessi, MD
Guest: Ronald DeVere, MD
Smell and taste loss can be the first sign of a serious neurologic disorder like Parkinson's or Alzheimer's disease, but it is also possible to lose these senses after something as simple as a sinus infection or virus. How can you help your patients get to the bottom of why this is happenning to them, and how can you help them cope with this change in their quality of life? Dr Ronald DeVere, director of the Taste and Smell Disorders Clinic in Austin, Texas, and author of the book Coping with Smell and Taste Loss,joins host Dr. Anthony Alessi to explain this strange, debilitating and frustrating phenomenon.
Host: Anthony Alessi, MD
Guest: Jeffrey Cohen, MD
For years, patients with multiple sclerosis have had to rely on injectable medications. But several new oral medications are emerging, and one drug has already been approved by the FDA. Why has it taken so long to develop oral formulations? Dr. Jeffrey Cohen, director of the Millen Experimental Therapeutics program at the Cleveland Clinic and professor of medicine at the Cleveland Clinic Lerner College of Medicine, joins host Dr. Anthony Alessi to discuss how these new drugs work, the side effects, and which patients can most benefit from new oral therapy.
Host: Anthony Alessi, MD
Guest: Eelco Wijdicks, MD, PhD
The American Academy of Neurology released new guidelines for determining brain death in adults, providing a step-by-step process for making this decision consistent among hospitals in the United States. One major departure in these guidelines is the recommendation of a single exam, rather than multiple exams occurring at several-hour intervals. How does this change impact organ donation following brain death? Dr. Eelco Wijdicks, professor of neurology at the Mayo Clinic College of Medicine and chair of the division of critical care, joins Dr. Anthony Alessi to discuss how to evaluate a brain dead patient without jeopardizing their organs for transplant.
Host: Anthony Alessi, MD
Guest: Carl Ansevin, MD
For the 12 million Americans who suffer from restless leg syndrome (RLS), the disease can often be misdiagnosed and misunderstood. Doctors as well as their patients are now more familiar with RLS due to the intense marketing of drugs used to treat restless legs syndrome. Host Dr. Anthony Alessi talks with Dr. Carl Ansevin, an adjunct faculty member in the department of biomedical sciences at Kent State University and sleep specialist at the Ohio Neurologic Institute in Boardman, Ohio, about how to properly diagnose and treat restless leg syndrome and which patients are more at risk of developing the disease.
Host: Anthony Alessi, MD
Guest: William Coplin, MD
The world witnessed a remarkable recovery after Congresswoman Gabrielle Giffords was shot in the head in an assassination attempt in January, 2011. However, most gunshot wounds to the head are fatal; statistics show only 5 percent of those shot in the head survive. Yet there are actions first responders and physicians can take to increase the chance of survival. Dr. William Coplin, associate professor of neurology and neurological surgery at Wayne State University in Detroit, Michigan, and director of neurotrauma and the neurological intensive care unit at Detroit Receiving Hospital, joins host Dr. Anthony Alessi to discuss what needs to be done in the "golden hour" after a shooting. He also focuses on the problems and rehabilitation issues patients face after this life-altering wound.
Host: Anthony Alessi, MD
Guest: David Simpson, MD
14 million Americans suffer migraine headaches every day. Many go untreated and many who are treated continue to have headaches. But an old drug proved to offer a new way to treat migraines, with the FDA approval of botulinum toxin injections for severe chronic migraine. Dr. David Simpson, professor of neurology at Mount Sinai School of Medicine in New York City and director of the clinical neurophysiology lab at Mount Sinai Hospital, joins host Dr. Anthony Alessi to discuss what patients qualify for this treatment, problems and risks associated with taking the injections, and the controversial results of the earlier clinical trials for this treatment.
Host: Anthony Alessi, MD
Guest: Don Iverson, MD
Nationwide there are an estimated several hundred thousand licensed drivers with Alzheimer's disease. A new study shows that more than half can still pass a road test, leaving physicians to help patients and caregivers decide when it's time to stop driving. Dr. Donald Iverson, lead author of the American Academy of Neurology's most recent guidelines on driving and dementia, joins host Dr. Anthony Alessi to discuss what tests are available to help make this decision, and how to approach the delicate discussion of this loss of independence with Alzheimer's patients.
Host: Anthony Alessi, MD
Guest: Mill Etienne, MD, MPH, CPH
Host Dr. Anthony Alessi interviews neurologist Lt. Cmdr. Mill Etienne, MD, at St. Damien's Pediatric Hospital in Port-au-Prince, Hati. Dr. Etienne is a Hatian-American physician in the United States military, stationed on the USNS Comfort. They discuss Dr. Etienne's work providing medical care, in addition to translation services and cultural sensitivity training for the staff on board the Comfort, and lessons he has brought from the American Academy of Neurology's Palatucci Advocacy Leadership Forum (which trains selected members to be effective advocates for patients at the local, state, and national levels.) At the end of the interview, find out how you can still help in Haiti.
Host: Anthony Alessi, MD
Guest: James Sejvar, MD
How is the CDC monitoring neurological complications from the H1N1 vaccine as it relates to the risk of Guillain-Barre syndrome? Dr. James Sejvar, neuroepidemiologist in the division of viral and rickettsial diseases at the National Center for Infectious Diseases and the Center for Disease Control and Prevention, outlines for host Dr. Anthony Alessi the historical association between swine flu vaccination and Guillain-Barre syndrome.
Host: Anthony Alessi, MD
Guest: Ralph Sacco, MD
Dr. Ralph Sacco, neurologist-in-chief at Jackson Memorial Hospital and the Miller Professor of Neurology, Epidemiology and Human Genetics at the Univeristy of Miami, joins host Dr. Anthony Alessi to discuss the FDA-approved treatment approaches for acute ischemic stroke, and what proportion of stokes each year are now treated with IV rTPA. Additionally, Dr. Sacco reviews the newly designated primary stroke centers throughout the United States, and how these have helped expand the treatement of stroke and organized healthcare professionals to provide the right treatment program for their patients in hospitals.
Host: Anthony Alessi, MD
Guest: Bruce Miller, MD
Alzheimer’s disease is the sixth leading cause of death in the United States. What advancements and treatments are available to help our patients through both the diagnosis, and prevent the onset? Dr. Bruce Miller, the A.W. and Mary Margaret Clausen Distinguished Professor of Neurology and Psychiatry and director of the Memory and Aging Center at the University of California, San Francisco, joins Dr. Anthony Alessi to discuss the state of Alzheimer's disease today, including how to help our patients who are just presenting with complaints of forgetfulness and fear of Alzheimer’s.
Host: Anthony Alessi, MD
Guest: Kevin Kerber, MD
Among the most baffling and often frustrating complaints that confront a physician is dizziness. What is the best approach for the dizzy patient and where is treatment today? Dr. Kevin Kerber, director of the Department of Neurology Dizziness Clinic and co-director of the Balance Disorders Clinical and Research Program in the department of neurology at the University of Michigan, joins Dr. Anthony Alessi to discuss how best to treat and manage the dizzy patient.
Host: Anthony Alessi, MD
Guest: Jeffrey Kutcher, MD
There are two causes of death in sports: cardiac and neurological. Dr. Jeffrey Kutcher joins host Dr. Anthony Alessi to explore the neurological causes of sudden death in sports. Dr. Kutcher is associate professor of neurology at the University of Michigan, director of Michigan NeuroSport, a multidisciplinary center dedicated to the evaluation and management of neurologic sports injuries, and chairs the sports neurology section of the American Academy of Neurology.
Host: Anthony Alessi, MD
Guest: Lily Jung, MD
What's new in the diagnosis and treatment of multiple sclerosis? Dr. Lily Jung, medical director of the Neurology Clinic and chief of neurology at Swedish Hospital Medical Center in Seattle, joins host Dr. Anthony Alessi to discuss the current state and future technologies available for the treatment of patients with MS.
Host: Anthony Alessi, MD
Guest: John England, MD
What is the best method to diagnose and treat patients with suspected neuropathies? Dr. John D. England, professor and head of the department of neurology at Louisiana State University Health Sciences Center, joins host Dr. Anthony Alessi to discuss the latest treatments for chronic neuropathic pain and peripheral neuropathy. Additionally, Dr. England explores the role of nerve biopsy, skin biopsy, and other methods used in the evaluation and diagnosis of neuropathy.
Host: Anthony Alessi, MD
Guest: Don Lewis, MD
How does a pediatric migraine differ from an adult migraine and what does the latest research in the treatment of pediatric migraine tell us? Dr. Don Lewis, professor of pediatrics and neurology at Eastern Virginia Medical School and pediatric neurologist at Children's Hospital of the King's Daughters, joins host Dr. Anthony Alessi to discuss both the nuances and treatments in pediatric medicine.
Host: Anthony Alessi, MD
Guest: Stephen Silberstein, MD
While the prevalence of migraine amongst Americans has remained fairly constant over the last fifteen years, our knowledge of migraine and the treatment options have grown significantly. What have we learned most recently about migraine and about vascular risks associated with migraine? Dr. Stephen Silberstein, professor of neurology and director of the Jefferson Headache Center at Thomas Jefferson University, joins host Dr. Anthony Alessi to discuss the latest research on treating migraine and the vascular risks associated with migraine.
Host: Anthony Alessi, MD
Guest: Jacqueline A. French, MD
Should special consideration be given to the substitution of antiepileptic drugs, and should antiepileptic prescriptions change for pregnant women? Dr. Jacqueline French, a professor in the department of neurology at the Comprehensive Epilepsy Center at New York University, joins host Dr. Anthony Alessi to discuss how to help determine which is best for your patient, and what key items to review when making the decision. Additionally, Dr. French explores the effect of pregnancy on antiepileptic drugs in women, and in which cases you should advise against antiepileptic drugs during pregnancy.